| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
207,851,000 |
| Market
Cap: |
11.18(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$32.18 - $59.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,000 |
1,000 |
| Total Buy Value |
$0 |
$0 |
$49,980 |
$49,980 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
387 |
387 |
11,063 |
116,582 |
| Total Sell Value |
$21,749 |
$21,749 |
$512,581 |
$11,151,362 |
| Total People Sold |
1 |
1 |
12 |
18 |
| Total Sell Transactions |
1 |
1 |
25 |
69 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kreuzburg Christa |
Director |
– • – |
2019-02-16 |
4 |
D |
$42.03 |
$15,047 |
D/D |
(358) |
5,018 |
|
- |
|
| Downie William |
SVP, Global Sales & Marketing |
• – – |
2019-02-15 |
4 |
AS |
$42.00 |
$307,230 |
D/D |
(7,315) |
34,926 |
|
- |
|
| Downie William |
SVP, Global Sales & Marketing |
• – – |
2019-02-15 |
4 |
D |
$42.00 |
$408,912 |
D/D |
(9,736) |
42,241 |
|
- |
|
| Downie William |
SVP, Global Sales & Marketing |
• – – |
2019-02-15 |
4 |
OE |
$20.50 |
$307,505 |
D/D |
12,457 |
44,912 |
|
- |
|
| Schmidt Kay A |
SVP, Technical OperationsOffic |
• – – |
2019-02-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,635 |
|
- |
|
| Fasman Steven L |
SVP & General Counsel |
• – – |
2019-01-28 |
4 |
D |
$36.49 |
$189,712 |
D/D |
(5,199) |
44,475 |
|
- |
|
| Greisch John J |
Director |
– • – |
2018-11-08 |
4 |
B |
$37.61 |
$488,930 |
I/I |
13,000 |
13,000 |
2.1 |
- |
|
| Miyamoto Lance |
SVP, Human Resources |
• – – |
2018-10-16 |
4 |
AS |
$42.50 |
$277,313 |
D/D |
(6,525) |
46,799 |
|
- |
|
| Miyamoto Lance |
SVP, Human Resources |
• – – |
2018-10-16 |
4 |
D |
$42.50 |
$487,688 |
D/D |
(11,475) |
53,324 |
|
- |
|
| Miyamoto Lance |
SVP, Human Resources |
• – – |
2018-10-16 |
4 |
OE |
$12.14 |
$218,520 |
D/D |
18,000 |
64,799 |
|
- |
|
| Littlejohns Barry |
President, Biologics & SDD |
• – – |
2018-10-15 |
4 |
AS |
$41.64 |
$1,968,115 |
D/D |
(47,265) |
37,718 |
|
- |
|
| Littlejohns Barry |
President, Biologics & SDD |
• – – |
2018-10-15 |
4 |
D |
$41.64 |
$4,061,815 |
D/D |
(97,546) |
84,983 |
|
- |
|
| Littlejohns Barry |
President, Biologics & SDD |
• – – |
2018-10-15 |
4 |
OE |
$14.86 |
$2,151,891 |
D/D |
144,811 |
104,599 |
|
- |
|
| Joseph Wetteny |
SVP & Chief Financial Officer |
• – – |
2018-10-15 |
4 |
D |
$41.47 |
$12,565 |
D/D |
(303) |
32,607 |
|
- |
|
| Chiminski John R |
Chair, President & CEO |
• • – |
2018-10-01 |
4 |
AS |
$45.32 |
$5,916,299 |
D/D |
(130,545) |
229,690 |
|
- |
|
| Chiminski John R |
Chair, President & CEO |
• • – |
2018-10-01 |
4 |
D |
$45.32 |
$9,046,235 |
D/D |
(199,608) |
360,235 |
|
- |
|
| Chiminski John R |
Chair, President & CEO |
• • – |
2018-10-01 |
4 |
OE |
$18.71 |
$6,027,735 |
D/D |
286,358 |
416,074 |
|
- |
|
| Morel Donald E Jr |
Director |
– • – |
2018-09-13 |
4 |
B |
$43.00 |
$430,000 |
D/D |
10,000 |
36,958 |
2.39 |
- |
|
| Chiminski John R |
Chair, President & CEO |
• • – |
2018-09-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,868 |
273,485 |
|
- |
|
| Downie William |
SVP, Global Sales & Marketing |
• – – |
2018-08-27 |
4/A |
D |
$43.66 |
$56,365 |
D/D |
(1,291) |
39,520 |
|
- |
|
| Maselli Alessandro |
SVP, Global Operations |
• – – |
2018-08-27 |
4/A |
D |
$43.66 |
$18,643 |
D/D |
(427) |
15,644 |
|
- |
|
| Hegwood Paul W Jr |
President, CSS |
• – – |
2018-08-27 |
4/A |
D |
$43.66 |
$22,048 |
D/D |
(505) |
9,587 |
|
- |
|
| Gunther Scott |
SVP, Quality & Reg. Affairs |
• – – |
2018-08-27 |
4/A |
D |
$43.66 |
$25,759 |
D/D |
(590) |
13,807 |
|
- |
|
| Joseph Wetteny |
SVP & Chief Financial Officer |
• – – |
2018-08-27 |
4/A |
D |
$43.66 |
$21,917 |
D/D |
(502) |
32,910 |
|
- |
|
| Arnold Jonathan |
President, Oral Drug Delivery |
• – – |
2018-08-27 |
4/A |
D |
$43.66 |
$22,616 |
D/D |
(518) |
32,696 |
|
- |
|
821 Records found
|
|
Page 22 of 33 |
|
|
0.18 (0.34%) 
